# Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)

> **NCT04031703** · PHASE3 · COMPLETED · sponsor: **Fudan University** · enrollment: 647 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Epirubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** 5-fluorouracil
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT04031703
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01-01
- **Primary completion:** 2016-04-20
- **Final completion:** 2016-04-20
- **Target enrollment:** 647 (ACTUAL)
- **Last updated:** 2020-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04031703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04031703, "Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04031703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*